TICKERNOMICS Sign up
Last Update: 2024-03-28 02:15:34
Eiger BioPharmaceuticals Inc. ( EIGR ) https://www.eigerbio.com
5.37USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-79.91%
EIGR
SPY
32.74%
-97.99%
EIGR
SPY
92.93%
-98.72%
EIGR
SPY
224.41%
-99.89%
EIGR
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
255.28
284.51
0.02
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.95
17.41
-159.15
-31.72
0.00
-3.77
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-527.52
96.42
-497.05
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
13.1474
-264.94
-100.95
2.38
Other Earnings and Cash Flow Stats:
Eiger BioPharmaceuticals Inc. ( EIGR ) Net Income TTM ($MM) is -93.81
Eiger BioPharmaceuticals Inc. ( EIGR ) Operating Income TTM ($MM) is -90.03
Eiger BioPharmaceuticals Inc. ( EIGR ) Owners' Earnings Annual ($MM) is 0.00
Eiger BioPharmaceuticals Inc. ( EIGR ) Current Price to Owners' Earnings ratio is 0.00
Eiger BioPharmaceuticals Inc. ( EIGR ) EBITDA TTM ($MM) is -89.12
Eiger BioPharmaceuticals Inc. ( EIGR ) EBITDA Margin is -497.05%
Capital Allocation:
Eiger BioPharmaceuticals Inc. ( EIGR ) has paid 0.00 dividends per share and bought back -2.691957 million shares in the past 12 months
Eiger BioPharmaceuticals Inc. ( EIGR ) has increased its debt by 0.454 million USD in the last 12 months
Capital Structure:
Eiger BioPharmaceuticals Inc. ( EIGR ) Interest-bearing Debt ($MM) as of last quarter is 41
Eiger BioPharmaceuticals Inc. ( EIGR ) Annual Working Capital Investments ($MM) are 12
Eiger BioPharmaceuticals Inc. ( EIGR ) Book Value ($MM) as of last quarter is -2
Eiger BioPharmaceuticals Inc. ( EIGR ) Debt/Capital as of last quarter is -2566%
Other Balance Sheet Stats:
Eiger BioPharmaceuticals Inc. ( EIGR ) has 27 million in cash on hand as of last quarter
Eiger BioPharmaceuticals Inc. ( EIGR ) has 16 million of liabilities due within 12 months, and long term debt 40 as of last quarter
Eiger BioPharmaceuticals Inc. ( EIGR ) has 44 common shares outstanding as of last quarter
Eiger BioPharmaceuticals Inc. ( EIGR ) has 0 million USD of preferred stock value
Academic Scores:
Eiger BioPharmaceuticals Inc. ( EIGR ) Altman Z-Score is -13.29 as of last quarter
Eiger BioPharmaceuticals Inc. ( EIGR ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Eiger BioPharmaceuticals Inc. ( EIGR ) largest shareholder is owning shares at 0.00 ($MM) value
Richard A Kayne(an insider) Bought 779 shares of Eiger BioPharmaceuticals Inc. ( EIGR ) for the amount of $7011.00 on 2023-11-02
11.73% of Eiger BioPharmaceuticals Inc. ( EIGR ) is held by insiders, and 62.35% is held by institutions
Eiger BioPharmaceuticals Inc. ( EIGR ) went public on 2014-01-30
Other Eiger BioPharmaceuticals Inc. ( EIGR ) financial metrics:
FCF:-81.93
Unlevered Free Cash Flow:-87.39
EPS:-1.63
Operating Margin:-527.52
Gross Profit Margin:96.42
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:4496.26
Beta:2.38
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Eiger BioPharmaceuticals Inc. ( EIGR ) :
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.